Investigating the exact molecular mechanisms by which NETs exert their effects is crucial for a complete understanding of their pathological impact and for the development of targeted PAD4 inhibitors or NET-modulating therapies leading to effective and safe treatments for the multifaceted challenges posed by obesity-associated metabolic disorders. The gene discussed is PADI4; the disease is obesity due to melanocortin 4 receptor deficiency.